2025.12.31Enrollment of phase-2 myopia control trial (NCT06579287) of Sunhawk vision had successfully completed on December 31, 2025.
2025.12.10Sunhawk Vision received the approval of Australia patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).
2025.11.03Sunhawk Vision submitted the request to U.S. FDA for Orphan Drug Designation (ODD) for SHJ002 ophthalmic solution in treating recurrent corneal erosion in patients with Sjogren’s syndrome.
2025.10.07The eye drop SHJ002 for the treatment of dry eye disease has completed the submission of the Investigational New Drug (IND) application for phaseIII clinical trials to the U.S. FDA.
2025.09.22Sunhawk Vision received the approval of Japanese patent for the company’s novel eye drops, SHJ002, in treating ocular surface diseases (including dry eye disease).
2025.07.29Sunhawk Vision has signed a contract with a U.S. pharmaceutical company with 30 years of manufacturing experience and is scheduled to manufacture clinical trial ophthalmic solution in the United States in August 2025.
2025.05.20Preliminary results of Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome
2025.05.06The clinical data on the Phase-II trial for corneal erosion in patients with Sjogren’s syndrome (NCT06381986) were locked on May 5, 2025. The data were unblinded and under statistical analysis.
2025.04.15Sunhawk Vision has completed all subject assessments in its Phase II clinical trial evaluating the treatment of corneal erosion in patients with Sjogren’s syndrome.
2025.02.27Sunhawk Vision has been registration as an Emerging Stock approved by the Taipei Exchange (OTC) Trading Center, meanwhile trading will commence from March 10, 2025.
2025.01.14The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.
2024.10.09The 2024 Nobel Prize in Physiology or Medicine has been awarded for the discovery of microRNA.
2024.07.26Received the Outstanding Biotechnology Industry Award from the Taiwan Bio Industry Organization.
2024.06.14The company has been approved for public issuance of shares and the stock symbol is 「7759」.
2024.05.02Received authorization from the U.S. FDA to commence a Phase II clinical trial for myopia control in children.
